Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Determination of time to onset and rate of action of insulin products: importance and new approaches.

Jain L, Parks MH, Sahajwalla C.

J Pharm Sci. 2013 Jan;102(1):271-9. doi: 10.1002/jps.23355. Epub 2012 Nov 6.

PMID:
23132625
2.

Measurement of insulin absorption and insulin action.

Heinemann L, Anderson JH Jr.

Diabetes Technol Ther. 2004 Oct;6(5):698-718. Review.

PMID:
15628821
4.

Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.

Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA.

Diabetes Care. 2010 May;33(5):1009-12. doi: 10.2337/dc09-2118. Epub 2010 Feb 11.

5.
6.

Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.

Nosek L, Roggen K, Heinemann L, Gottschalk C, Kaiser M, Arnolds S, Heise T.

Diabetes Obes Metab. 2013 Jan;15(1):77-83. doi: 10.1111/j.1463-1326.2012.01677.x. Epub 2012 Sep 9.

PMID:
22882249
8.

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

Clin Ther. 2000 Feb;22(2):222-30.

PMID:
10743981
9.

Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.

Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S, Heinemann L.

Diabet Med. 1998 Sep;15(9):747-51.

PMID:
9737803
10.
11.

AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics.

de la Peña A, Seger M, Rave K, Heinemann L, Silverman B, Muchmore DB.

Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S75-80. doi: 10.1089/dia.2009.0057.

PMID:
19772452
12.
13.

U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.

Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S.

Diabetes Obes Metab. 2012 Mar;14(3):222-7. doi: 10.1111/j.1463-1326.2011.01516.x. Epub 2011 Nov 13.

PMID:
21981286
14.

Increased action of pulsatile compared to non-pulsatile insulin delivery during a meal-like glucose exposure simulated by computerized infusion in healthy humans.

Juhl CB, Gjedsted J, Nielsen MF, Schmitz O.

Metabolism. 2012 Aug;61(8):1177-81. doi: 10.1016/j.metabol.2011.12.014. Epub 2012 Mar 3.

PMID:
22386942
15.

Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions.

Freckmann G, Pleus S, Haug C, Bitton G, Nagar R.

J Diabetes Sci Technol. 2012 Jul 1;6(4):780-5. Review.

16.

The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study.

Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco-Kent D, Liu C, Krasner A.

Diabetes Care. 2005 Sep;28(9):2161-9.

PMID:
16123484
17.

Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.

Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV.

Pediatr Diabetes. 2013 May;14(3):168-73. doi: 10.1111/pedi.12001. Epub 2012 Oct 28.

18.

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.

Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE.

Diabetes Care. 2013 Feb;36(2):273-5. doi: 10.2337/dc12-0808. Epub 2012 Oct 5.

19.

Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects.

Gern JE, Stone CK, Nakano M, Muchmore DB, de la Peña A, Park S, Suri A, Tibaldi F, Soon D, Busse WW.

Clin Pharmacol Ther. 2008 Feb;83(2):307-11. Epub 2007 Jul 11.

PMID:
17625517

Supplemental Content

Support Center